Gateway to Think Tanks
来源类型 | Working Paper |
规范类型 | 报告 |
DOI | 10.3386/w17226 |
来源ID | Working Paper 17226 |
Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets | |
Patricia M. Danzon; Michael F. Furukawa | |
发表日期 | 2011-07-20 |
出版年 | 2011 |
语种 | 英语 |
摘要 | This paper examines the role of regulation and competition in generic markets. Generics offer large potential savings to payers and consumers of pharmaceuticals. Whether the potential savings are realized depends on the extent of generic entry and uptake and the level of generic prices. In the U.S., the regulatory, legal and incentive structures encourage prompt entry, aggressive price competition and patient switching to generics. Key features are that pharmacists are authorized and incentivized to switch patients to cheap generics. By contrast, in many other high and middle income countries, generics traditionally competed on brand rather than price because physicians rather than pharmacies are the decision-makers. Physician-driven generic markets tend to have higher generic prices and may have lower generic uptake, depending on regulations and incentives. |
主题 | Health, Education, and Welfare ; Health ; Other ; Law and Economics ; Industrial Organization ; Regulatory Economics ; Industry Studies |
URL | https://www.nber.org/papers/w17226 |
来源智库 | National Bureau of Economic Research (United States) |
引用统计 | |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/574904 |
推荐引用方式 GB/T 7714 | Patricia M. Danzon,Michael F. Furukawa. Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets. 2011. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
w17226.pdf(371KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。